Trial Profile

An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALLN 346 (Primary)
Indications Gout; Hyperuricaemia
Focus Adverse reactions; Proof of concept
Acronyms Study 201
Sponsors Allena Pharmaceuticals

Most Recent Events

20 Jun 2023 Status changed from recruiting to completed.
19 Jul 2022 According to an Allena Pharmaceuticals media release, company plans to provide an update on topline safety and efficacy data that includes all 16 patients enrolled in this study during Q3 2022.
04 Jun 2022 Results (n=11)presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com